Cargando…
Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin—folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial
BACKGROUND: Often curative treatment for locally advanced resectable esophageal or gastro-esophageal junctional cancer consists of concurrent neoadjuvant radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy regimens in this setting is a combination...
Autores principales: | Messager, Mathieu, Mirabel, Xavier, Tresch, Emmanuelle, Paumier, Amaury, Vendrely, Véronique, Dahan, Laetitia, Glehen, Olivier, Vasseur, Frederique, Lacornerie, Thomas, Piessen, Guillaume, El Hajbi, Farid, Robb, William B., Clisant, Stéphanie, Kramar, Andrew, Mariette, Christophe, Adenis, Antoine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872363/ https://www.ncbi.nlm.nih.gov/pubmed/27194176 http://dx.doi.org/10.1186/s12885-016-2335-9 |
Ejemplares similares
-
Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome
por: Adenis, Antoine, et al.
Publicado: (2013) -
Nezahualcóyotl, Acolmiztli, 1402-1472
por: Alva Ixtlilxóchitl, Fernando de, 1402-1472
Publicado: (1972) -
Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking
por: Jarraya, Hajer, et al.
Publicado: (2013) -
MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2021) -
Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer
por: Conroy, T, et al.
Publicado: (2010)